Compare MXE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | TIL |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 54.8M |
| IPO Year | 1994 | 2021 |
| Metric | MXE | TIL |
|---|---|---|
| Price | $13.25 | $7.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 3.0K | ★ 15.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.21 | $5.67 |
| 52 Week High | $14.30 | $33.83 |
| Indicator | MXE | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 46.86 |
| Support Level | $12.66 | $7.59 |
| Resistance Level | $13.93 | $8.30 |
| Average True Range (ATR) | 0.22 | 0.30 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 61.79 | 52.05 |
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.